Singapore hospital tests novel RNA therapy in fight against advanced liver cancer
NCT ID NCT05097911
Summary
This early-stage study is testing the safety and best dose of a new three-drug combination for people with advanced liver cancer (hepatocellular carcinoma) who haven't had other drug treatments. The combination adds a new experimental RNA drug (MTL-CEBPA) to two existing cancer drugs (atezolizumab and bevacizumab). Researchers will enroll about 33 patients to see how well the body handles the drugs and to look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.